We're for the peak performers

Sustained Disease Control with EYLEA® 8mg: the first and only approved anti-VEGF that allows for interval extensions up to 5 months

EYLEA 8mg is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) and visual impairment due to diabetic macular oedema (DME).

Introducing the EYLEA® 8mg pre-filled syringe, OcuClick.
Discover how you and your patients can benefit from a simple preparation process by clicking below.

Find out more

Lasting control of disease activity could redefine treatment expectations for your patients

Injection frequency impacts treatment experience

Resilience of fluid control can impact treatment outcomes

Vision gains can be difficult to maintain

Sustained Disease Control with EYLEA 8mg is the ability to achieve greater and longer lasting control of disease activity vs. Eylea 2mg

Lasting vision gains maintained with extended intervals

Unprecedented extensions:

~8/10 (nAMD) and ~9/10 (DME) patients randomised to the q16 arm had a last assigned  treatment interval of ≥q16 through Week 96
½ of nAMD/DME patients had a last assigned  treatment interval of q20 or more

Rapid and resilient fluid control:

Superior fluid control at Week 16 vs EYLEA 2mg   (nAMD): p=0.0002. Fluid control maintained   through Week 96 (nAMD and DME)

We're for those who want more for their nAMD and DME patients

Now your nAMD and DME patients have the potential to benefit from Sustained Disease Control with EYLEA 8mg

Why a higher dose of EYLEA?

Learn more about the EYLEA Mode of Action

nAMD trial data

Discover PULSAR efficacy data

DME trial data

Discover PHOTON efficacy data

With only 3 loading doses, as few as 5 injections in Year 1 and a safety profile consistent with EYLEA 2mg

Explore

Safety

Explore the EYLEA 8mg safety data in nAMD and DME patients

Dosing

Discover the posology of EYLEA 8mg

How to inject EYLEA 8mg

Learn the key steps in injecting EYLEA 8mg

Abbreviations
2q8: 2mg every 8 weeks.
BCVA: best-corrected visual acuity.
DME: diabetic macular oedema.
MoA: mode of action.
nAMD: neovascular (wet) age-related macular degeneration.
q8: every 8 weeks.
q16: every 16 weeks.

^{*in the UK and EU.}

^{PP-EYL_8mg-ALL-0037-1}

nAMD

References
1
EYLEA® 8mg (aflibercept 114.3 mg/mL, solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG.
2
Korobelnik J-F. Aflibercept 8 mg in patients with neovascular age-related macular degeneration: Phase 3 PULSAR trial 96-week results. AAO. 3–6 November 2023. San Francisco, USA. Oral presentation.
3
Do D. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. AAO. 3–6 November 2023. San Francisco, USA. Oral presentation.
4
Kaiser PK, et al. Retina 2021;41:1579–1586.
5
Balaskas K, et al. Ophthalmol Ther 2021;10:231–243.
6
Khachigian LM, et al. J Transl Med 2023;21:133.
7
Chong Teo K-Y, et al. Retina 2022;42:95–106.
8
Iglicki M, et al. Eye (Lond) 2022;36:273–277.
9
Loewenstein A, et al. EURETINA 2023 global survey nAMD. EURETINA 2023. 5–8 October 2023. Amsterdam, The Netherlands.
10
Lanzetta P, et al. Graefes Arch Clin Exp Ophthalmol 2017;255:1259–1273.
11
Patel P & Sheth V. J Clin Med 2021;10:2436.
12
Xu M, et al. Drug Des Devel Ther 2022;16:3241–3262.
13
Monés J, et al Ophthalmologica 2020;243:1–8.
14
Klufas MA, et al. Targeting unmet needs in nAMD treatment: Retina Specialist 2018. Available at: https://www.retina-specialist.com/article/targeting-unmet-needs-in-namd-treatment. Accessed: November 2023.
15
Ricci F, et al. Int J Mol Sci 2020;21:8242.
16
Cozzi M, et al. Graefes Arch Clin Exp Ophthalmol 2022;260:781–789.
17
Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-Week results from the Phase 3 PULSAR trial. Retina Society 55th Annual Scientific Meeting. 2–5 November 2022. Pasadena, USA. Oral presentation.
Footnotes
a
Greater and longer lasting control of disease activity vs. EYLEA 2q8.¹²،¹³
b
Primary endpoint at Week 48: mean change in BCVA (non-inferiority).¹²،¹³
c
EYLEA (aflibercept) 2mg was dosed at fixed q8 intervals after 3 (nAMD) or 5 (DME) initial monthly injections.¹²،¹³
d
Patients could receive as few as 5 injections per dosing schedule within the trial protocol.¹²،¹³
e
Loading doses refers to the initial monthly dosing phase.